SGLT2 Inhibitors in Type 2 Diabetes After Acute Heart Attack
Observes SGLT2 inhibitor drug use in adults with type 2 diabetes and recent heart attack.
Key facts
- Who runs it
- Kiyuk Chang
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 1 Aug 2020
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Treatments tested
- SGLT2 inhibitor
- Record updated
- 3 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who had a heart attack treated with a procedure to open the heart arteries (PCI), and who started an SGLT2 inhibitor medicine around that time.
- Age
- 19 years and older
- Sex
- All sexes can join.
- Disease stage
- Acute myocardial infarction (heart attack) treated with percutaneous coronary intervention (PCI), together with type 2 diabetes mellitus.
- Earlier treatment
- Must have started an SGLT2 inhibitor less than 1 month before or after the PCI. Must not have used an SGLT2 inhibitor before.
Main reasons for not taking part
- Type 1 diabetes
- Users of insulin or GLP-1 analogue medicines
- Previous users of SGLT2 inhibitors
- Pregnancy
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Acute myocardial infarction who were treated with percutaneous coronary intervention
- Type 2 diabetes mellitus
- Started SGLT2 inhibitors <1 month before/after PCI
Who cannot take part
- Previous users of SGLT2 inhibitors
- Type 1 diabetes mellitus
- Insulin / GLP-1 analogue users
- Pregnancy
Where in South Korea
- Seoul St. Mary's HospitalSeoul, South KoreaContact: Kiyuk ChangTaking people
About the trial
What the trial wants to find out
Prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that SGLT2 inhibitors reduce cardiovascular risk. No studies have yet examined the occurrence of cardiovascular disease in patients with acute myocardial infarction.
Read full original descriptionShow less
The investigators designed the current study to evaluate the most ideal oral hypoglycemic agent in type 2 diabetes patients undergoing percutaneous coronary intervention for acute myocardial infarction. The investigators hypothesize that the use of SGLT-2 inhibitors will reduce cardiovascular events and modify left ventricular remodeling after myocardial infarctions.
The group in the trial
- SGLT-2 inhibitor
Patients with naive use of SGLT-2 inhibitors after PCI
Treatment: SGLT2 inhibitor
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Real World Observation of SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study
- Plain-language title
- SGLT2 Inhibitors in Type 2 Diabetes After Acute Heart AttackGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 January 2025